```html

Kawasaki Disease (Incomplete) – A Patient‑Friendly Guide

Overview

Kawasaki disease (KD) is an acute, self‑limited vasculitis that predominantly affects medium‑size arteries, especially the coronary arteries. When a child meets only some of the classic diagnostic criteria, the condition is termed incomplete or atypical Kawasaki disease. Early recognition is crucial because untreated KD can cause permanent heart damage.

Who it affects

• Age: most cases occur in children under 5 years, with a peak at 18‑24 months.
• Gender: males are about 1.5‑1.7 times more likely than females.
• Ethnicity: higher incidence in Asian populations, especially Japanese (≈ 264 per 100,000 children < 5 y) and Korean children. In the United States, the overall rate is about 20 per 100,000 children < 5 y, with the highest rates among Asian‑American children.

Prevalence

Globally, Kawasaki disease is the leading cause of acquired heart disease in children in developed nations. In the United States, ≈ 5,000–6,000 new cases are reported each year (CDC, 2023). Incomplete KD accounts for 15‑20% of all KD presentations, making it a frequent diagnostic challenge.

Symptoms

Classic KD requires fever ≥5 days plus ≥4 of 5 principal features. Incomplete KD presents with fever plus fewer of those features, but other clues (laboratory & echocardiographic findings) support the diagnosis.

Core symptoms (present in most cases)

• Fever – Usually high (≥39 °C / 102.2 °F), persistent, and unresponsive to usual antipyretics.
• Changes in the extremities – Swelling or erythema of hands/feet in the acute phase; later, periungual desquamation (peeling) of fingertips and toes.
• Rash – Polymorphous, non‑vesicular rash that can appear on the trunk, groin, or extremities.
• Conjunctival injection – Bilateral non‑purulent redness of the eyes without discharge.
• Oral changes – “Strawberry tongue,” erythema of the lips and oral mucosa, cracking or fissuring of corners of the mouth.
• Cervical lymphadenopathy – Typically a single, >1.5 cm, tender node in the anterior neck.

Features more common in incomplete KD

• Fewer than 4 principal clinical signs (often only fever + 1‑2 others).
• Prominent laboratory abnormalities (see Diagnosis section).
• Early coronary artery changes on echocardiography despite limited clinical signs.

Red‑flag symptoms that suggest possible heart involvement

• Chest pain or tightness.
• Shortness of breath, especially with activity.
• Palpitations or irregular heart rhythm.
• Sudden onset of swelling in the feet or hands (may indicate aneurysm formation).

Causes and Risk Factors

The exact trigger for Kawasaki disease remains unknown, but current evidence points to a combination of genetic susceptibility and an abnormal immune response to an infectious agent.

Possible causes

• Infectious hypothesis – Seasonal peaks and clustering of cases suggest a viral or bacterial trigger (e.g., coronaviruses, adenovirus, or certain superantigen‑producing bacteria).
• Genetic predisposition – Polymorphisms in genes related to immune regulation (e.g., ITPKC, CD40, BLK) increase risk (NIH, 2022).
• Immune dysregulation – Over‑activation of cytokines (TNF‑α, IL‑6, IL‑1β) leads to widespread vascular inflammation.

Risk factors

• Age < 5 years, especially 6‑24 months.
• Male sex.
• Asian ancestry (Japanese, Korean, Chinese, Filipino).
• Sibling or family member with KD (≈ 2% familial clustering).
• Seasonal exposure – higher incidence in winter–spring in temperate climates.

Diagnosis

Diagnosing incomplete KD is a stepwise process that blends clinical judgment with laboratory and imaging data.

Clinical criteria

1. Fever ≥5 days (or ≥3 days if coronary changes are already evident).
2. Presence of 2 or fewer of the classic signs (rash, conjunctivitis, oral changes, extremity changes, lymphadenopathy).
3. Exclusion of other febrile illnesses (e.g., scarlet fever, viral exanthems, toxic‑shock syndrome).

Key laboratory tests

• Complete blood count (CBC) – Elevated white blood cells (often >15 × 10⁹/L), neutrophilia, anemia, and thrombocytosis (platelets >450 × 10⁹/L after week 2).
• Inflammatory markers – C‑reactive protein (CRP) >3 mg/dL or erythrocyte sedimentation rate (ESR) >40 mm/hr.
• Liver enzymes – Mild transaminitis (ALT/AST ↑).
• Urinalysis – Sterile pyuria (≥10 WBC/hpf) in 30‑50% of cases.
• Albumin – Hypoalbuminemia (<3.5 g/dL) may signal higher risk of coronary aneurysms.

Echocardiography

2‑D transthoracic echocardiogram is the cornerstone imaging test.

• Detects coronary artery dilation or aneurysm (Z‑score ≥ 2.5).
• Assesses ventricular function, valvular regurgitation, and pericardial effusion.
• Must be performed at diagnosis and repeated at 2‑week, 6‑week, and 6‑month intervals per AHA guidelines.

Additional imaging (if needed)

• Cardiac MRI or CT angiography – for detailed coronary anatomy if echocardiography is inconclusive.
• Chest X‑ray – rarely needed, but can show cardiomegaly in severe cases.

Diagnostic algorithm (simplified)

1. Fever ≥5 days + any clinical features → consider KD.
2. If <4 classic signs, obtain labs & echo.
3. Laboratory evidence of inflammation + coronary changes → diagnosis of incomplete KD.
4. If labs are equivocal, repeat clinical assessment and echo in 48‑72 h.

Treatment Options

Prompt therapy within the first 10 days of illness dramatically reduces the risk of coronary artery aneurysms—from ~25% to <5% when treated appropriately.

First‑line medications

• Intravenous immunoglobulin (IVIG) – 2 g/kg as a single infusion over 10‑12 hours. Evidence shows >90% fever resolution within 48 h.
• Aspirin – High‑dose (80‑100 mg/kg/day) divided every 6 h during the acute febrile phase, then low‑dose (3‑5 mg/kg/day) for antiplatelet effect until 6‑8 weeks or longer if coronary abnormalities persist.

Adjunctive therapy for IVIG‑resistant cases

Approximately 10‑20% of children do not respond to the initial IVIG dose (persistent fever ≥36 h).

• Second dose of IVIG (2 g/kg) – most common next step.
• Corticosteroids – Methylprednisolone 30 mg/kg IV daily for 1‑3 days, then oral taper; especially useful in high‑risk patients (e.g., young age, high CRP, coronary dilation).
• Biologic agents – Infliximab (TNF‑α inhibitor) 5 mg/kg IV, or Anakinra (IL‑1 receptor antagonist) 2‑4 mg/kg/day, reserved for refractory disease.

Supportive care

• Fluid management – maintain euvolemia; avoid over‑hydration that could stress the heart.
• Antipyretics – acetaminophen for comfort (avoid NSAIDs except aspirin in KD).
• Monitoring – daily temperature checks, heart rate, and blood pressure while inpatient.

Lifestyle & activity recommendations during acute phase

• Bed rest or limited activity until fever resolves.
• Avoid contact sports for at least 4‑6 weeks after fever cessation, especially if coronary changes are present.

Living with Kawasaki disease (incomplete)

Even after the acute illness, many families have lingering questions about long‑term health. Below are practical tips for day‑to‑day management.

Follow‑up schedule

• Week 2 – Repeat echocardiogram; adjust aspirin dose.
• Week 6 – Echocardiogram to assess for resolution of any coronary changes.
• 6 months – Final standard echo for most children without persistent aneurysms.
• Patients with coronary aneurysms >5 mm require lifelong cardiology follow‑up (often yearly).

Medication adherence

• Use a pill organizer and set alarms for aspirin doses.
• Inform school nurses of the aspirin regimen and any bleeding precautions.
• Report any bruising, gum bleeding, or black stools to the pediatrician promptly.

Healthy habits

• Balanced diet rich in fruits, vegetables, whole grains, and lean protein – supports vascular health.
• Regular age‑appropriate physical activity once cleared by a cardiologist.
• Maintain a healthy weight; obesity can increase cardiovascular risk later in life.
• Stay up‑to‑date on vaccinations; no contraindication for routine immunizations after the acute phase.

Psychosocial support

• Explain the disease in simple terms to the child; reassurance reduces anxiety.
• Connect families with support groups (e.g., Kawasaki Disease Foundation).
• Monitor for school‑related concerns—children may need a short exemption from strenuous activities.

Prevention

Because the trigger is still unidentified, primary prevention is limited. However, measures that reduce infection risk may indirectly lower incidence.

• Encourage regular hand‑washing and respiratory hygiene, especially during winter outbreaks.
• Prompt treatment of bacterial infections (e.g., streptococcal pharyngitis) to avoid possible superantigen exposure.
• Breastfeeding for at least 6 months may provide protective immune factors, though data are indirect.

Families with a history of KD should discuss genetic counseling with their pediatrician, though no specific screening test exists.

Complications

If untreated or inadequately treated, Kawasaki disease can have serious sequelae.

• Coronary artery aneurysms (CAAs) – Occur in ≈ 25% of untreated cases; risk of thrombosis or myocardial infarction.
• Myocarditis – Inflammation of heart muscle leading to reduced ejection fraction.
• Valvular regurgitation – Most commonly mild mitral or aortic regurgitation, usually transient.
• Peripheral artery stenosis – Rare, can affect limbs.
• Persistent fever or systemic inflammation – May lead to prolonged hospitalization.
• Long‑term cardiovascular disease – Adults who had KD, especially with prior CAA, have higher rates of hypertension, dyslipidemia, and premature atherosclerosis.

When to Seek Emergency Care

References

• American Heart Association. 2020 Guidelines for the Diagnosis, Management, and Long‑Term Care of Kawasaki Disease. Circulation. 2020;141:e367‑e399.
• Cleveland Clinic. Kawasaki Disease – Symptoms, Causes, Treatment. Retrieved May 2024.
• Centers for Disease Control and Prevention. Kawasaki Disease Data and Statistics. Updated 2023.
• National Institutes of Health. Genetics of Kawasaki Disease. NIH Roadmap, 2022.
• Mayo Clinic. Kawasaki disease: Diagnosis and treatment. Accessed 2024.
• World Health Organization. Global surveillance of vasculitis syndromes. WHO Press, 2021.

```